A case of palmoplantar pustulosis induced by certolizumab pegol: New anti-TNF-alpha demonstrates the same class effect Article

cited authors

  • Shelling, ML; Vitiello, M; Lanuti, EL; Miteva, M; Romanelli, P; Kerdel, FA

fiu authors


  • The development of de novo psoriasis in patients treated with tumor necrosis factor-alpha antagonists is well recognized. The authors hereby report a case of palmplantar pustular psoriasis in a patient with rheumatoid arthritis treated with etanercept. The condition responded to topical steroids but re-occurred upon treating the patient with certolizumab pegol. This strongly suggests that the development of de novo psoriasis is a class effect.

publication date

  • August 1, 2012

start page

  • 40

end page

  • 41


  • 5


  • 8